Boothbay Fund portfolio shifts
Boothbay Fund Management boosts stakes in key REITs and biotech firm, adds new industrial supplier
Anonymous
Key Points
1
In Camden Property Trust (CPT), Boothbay reported owning 98,301 shares after adding 92,873 shares in the fourth quarter, and the company disclosed a quarterly dividend that will be paid on Friday, July 17.
2
For Regency Centers (REG), Norges Bank purchased a new position in Q4 valued at about $1.1837 billion. Analyst notes cited in the filings also included Barclays raising its price target from $85.00 to $90.00 with an “overweight” rating (May 12) and UBS lifting its target from $75.00 to $81.00 with a “neutral” rating (May 18).
3
In Vaxcyte (PCVX), Caligan Partners LP bought a new position in Q4 worth approximately $78.66 million, and Paradigm Biocapital Advisors LP was also a large new/expanded holder (4,068,020 shares worth about $187.70 million). The article also states 96.78% of PCVX is owned by institutional investors.
4
For CareTrust REIT (CTRE), Boothbay owned 347,008 shares after acquiring an additional 50,216 shares in the fourth quarter (0.16% stake worth about $12.55 million). The article adds that 87.77% of CTRE is owned by institutional investors and lists a 50-day moving average of $39.41 versus a 200-day moving average of $38.48.
5
For Parker-Hannifin (PH), Boothbay initiated the position with 12,189 shares valued at approximately $10.714 million. The cited analyst coverage was mixed but specific: Mizuho set a $1,050 price target (May 1) and Evercore set a $1,064 target (May 11), while Wall Street Zen downgraded the stock from “buy” to “hold” on June 6.
Boothbay Fund Management LLC made a big bet on real estate last quarter. The New York-based hedge fund added 92,873 shares of Camden Property Trust (CPT) in Q4, ending with 98,301 shares worth about $10.82 million, according to Watchlist News.
The move was part of a broader shift by Boothbay into real estate investment trusts (REITs) — properties that pay regular dividends. The firm also expanded stakes in Regency Centers and CareTrust REIT, and started a fresh position in industrial giant Parker-Hannifin.
Boothbay Piles Into Camden Ahead of July Dividend
Boothbay's Camden stake grew by 1,711% in a single quarter. The fund now owns about 0.10% of the company, per Watchlist News. Camden Property Trust focuses on apartment communities, mainly in Sun Belt cities like Dallas and Atlanta. The stock is trading close to both its 50-day and 200-day moving averages, a sign of price stability.
Camden is set to pay a quarterly dividend on July 17, 2026. That date may have influenced Boothbay's timing. Funds sometimes buy shares before a dividend payout to capture the yield. CEO Ric Campo has pointed to Sun Belt migration trends as a long-term driver of rental demand.
Norges Bank's $1.18B Regency Bet Draws Analyst Attention
Boothbay also raised its Regency Centers stake to roughly 0.08% of the company. But the bigger story is Norway's sovereign wealth fund. Norges Bank opened a brand-new position in Regency Centers worth $1.1837 billion in Q4. That's one of the largest single institutional bets on retail real estate this year.
Analysts took notice. Barclays raised its price target on Regency from $85 to $90 with an
Analysts took notice. Barclays raised its Regency Centers price target from $85 to $90 with an "overweight" rating on May 12. UBS followed on May 18, lifting its target from $75 to $81 but keeping a "neutral" rating — suggesting the stock is solid but may not have much room to run.
CareTrust REIT Draws 88% Institutional Ownership as Aging Population Thesis Builds
Boothbay added 50,216 shares of CareTrust REIT (CTRE) in Q4, bringing its total to 347,008 shares worth about $12.55 million — a 0.16% stake. CareTrust focuses on healthcare properties like nursing facilities. Its 50-day moving average sits at $39.41, above the 200-day average of $38.48. That pattern, called a "golden cross," often signals a bullish trend.
Institutional investors now own 87.77% of CareTrust, per Watchlist News. That heavy concentration reflects a growing Wall Street bet on healthcare real estate as the U.S. population ages. CEO Jenny M. Hagel leads a portfolio that has quietly become a favorite among large fund managers.
Boothbay Starts Parker-Hannifin Position Amid Mixed Analyst Signals
Boothbay made one new industrial bet last quarter. The firm bought 12,189 shares of Parker-Hannifin (PH), valued at about $10.714 million. Parker-Hannifin makes motion and control systems used in factories and aerospace. Mizuho set a $1,050 price target on May 1. Evercore went slightly higher, setting a $1,064 target on May 11.
Not everyone is bullish. Wall Street Zen downgraded Parker-Hannifin from "buy" to "hold" on June 6, citing valuation concerns. The downgrade suggests some analysts think the stock's strong run may already reflect most of the good news. Boothbay's entry puts it in the middle of that debate.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
17
Reach
38
A
AnonymousAuthor
